Carlos A Canas 1 , Fabio Bonilla-Abadia 1 , Katherine Vallejo 1 , Hector M Rengifo 2 , Marco A Gallon 3 , Gabriel J Tobon 1 Show Affiliations »
Abstract
BACKGROUND AND OBJECTIVE: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6). METHODS: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up. RESULTS: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor. CONCLUSION: Tocilizumab could be an optional treatment in patients with TAO. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND AND OBJECTIVE: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease , occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6 ). METHODS: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient 's follow-up. RESULTS: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab , an antibody directed against the IL-6 receptor. CONCLUSION: Tocilizumab could be an optional treatment in patients with TAO. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Chemical
Disease
Gene
Species
Keywords:
Graves` associated ophthalmopathy; IL-6; Thyroid-associated ophthalmopathy; extrathyroidal manifestation; infiltrating cytokines; tocilizumab.
Mesh： See more »
Substances： See more »
Year: 2018
PMID： 29962351 DOI： 10.2174/1871530318666180702150243
Source DB: PubMed Journal: Endocr Metab Immune Disord Drug Targets ISSN： 1871-5303 Impact factor: 2.895